152 related articles for article (PubMed ID: 35156638)
1. What are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome?
Akleylek C; Gür SG; Sever İH; Koçulu Demir S; Çevik E; Eken E; Gökkaya Z; Çağatay Y; Yılmaz N
Eur J Rheumatol; 2022 Jul; 9(3):126-131. PubMed ID: 35156638
[TBL] [Abstract][Full Text] [Related]
2. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
[TBL] [Abstract][Full Text] [Related]
3. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.
de Cáceres C; Martínez R; Bachiller P; Marín L; García JM
Pharmacol Rep; 2020 Dec; 72(6):1529-1537. PubMed ID: 33165762
[TBL] [Abstract][Full Text] [Related]
4. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
5. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V; Birlutiu RM; Chicea L
Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
[TBL] [Abstract][Full Text] [Related]
8. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
[TBL] [Abstract][Full Text] [Related]
9. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
[TBL] [Abstract][Full Text] [Related]
10. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.
Pettit NN; Nguyen CT; Mutlu GM; Wu D; Kimmig L; Pitrak D; Pursell K
J Med Virol; 2021 Mar; 93(3):1459-1464. PubMed ID: 32790075
[TBL] [Abstract][Full Text] [Related]
11. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients.
Toda M; Fujii K; Yoshifuji A; Kondo Y; Itoh K; Sekine K; Kikuchi T; Ryuzaki M
Clin Exp Nephrol; 2022 Jan; 26(1):75-85. PubMed ID: 34436742
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
Kaya S; Kavak S
Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching.
Güçlü ÖA; Önal U; Akalın H; Öztürk NAA; Belik HÖ; Demirdöğen E; Dilektaşlı AG; Kazak E; Ocakoğlu G; Sağlık İ; Coşkun F; Ediger D; Heper Y; Ursavaş A; Yılmaz E; Uzaslan E; Karadağ M
Adv Clin Exp Med; 2022 Nov; 31(11):1197-1206. PubMed ID: 35951629
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
17. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
[TBL] [Abstract][Full Text] [Related]
18. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]